HP&M’s David Clissold to Present at 4th Annual CNS Diseases World Summit

June 18, 2014

GTCbio recently announced that it will be holding the 4th Annual CNS Diseases World Summit from September 18-19, 2014 in San Francisco, California.  The summit consists of two individual conferences that will run in parallel: (1) the 7th CNS Partnering & Deal-Making conference; and (2) the 8th Neurodegenerative Conditions Research & Development conference.   

Sessions and panel discussions for the 7th CNS Partnering & Deal-Making conference include:

  • New Approaches to Funding in the CNS
  • Private/Public Partnerships in Neuroscience Research
  • Joint Session with co-located Neurodegenerative Conditions Research & Development Conference: Rare CNS Diseases
  • Partnering & Licensing in the CNS
  • Up & Coming Trends and Other Considerations in Neuroscience
  • Investment Opportunities with Venture Capital
  • Private/Public Partnerships to Advance Research
  • Regulatory Considerations and Challenges in the CNS
  • New Partnership Structures in CNS R&D

Sessions for the 8th Neurodegenerative Conditions Research & Development conference include:

  • Novel Therapeutic Targets and Approaches in Alzheimer's Disease
  • Drug Mechanisms and Treatments in Parkinson’s Disease
  • New Approaches and Treatments in Neurodegenerative and Neuropsychiatric Conditions
  • Joint Session with CNS Partnering & Deal-Making Conference: Rare CNS Diseases
  • Biomarkers: Translation from Discovery to Clinical

Hyman, Phelps & McNamara, P.C’s David B. Clissold is scheduled to present at the conference.  As such, we’re able to offer FDA Law Blog readers a special 25% discount off of the regular price.  To obtain the discount, please use colleague code HPMCNS25 when registering for the conference

Categories: Drug Development